A pramipexol retard klinikai vizsgálatai

Translated title of the contribution: Clinical studies on pramipexol retard

Research output: Contribution to journalArticle

1 Citation (Scopus)


Pramipexol retard is the newest drug for the treatment of Parkinson's disease. The prolonged release of the agent in this preparation allows a more continuous dopaminergic stimulation than previous preparations, without reducing the agent's already known and proven clinical efficiency. In addition, it has a more favourable adverse effect profile than previous preparations, and patient compliance can also be better as it needs to be taken only once daily. These benefits have been proven in recent clinical studies, of which the most important ones are reviewed here.

Translated title of the contributionClinical studies on pramipexol retard
Original languageHungarian
Pages (from-to)171-174
Number of pages4
JournalIdeggyogyaszati szemle
Issue number5-6
Publication statusPublished - May 30 2010

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Clinical studies on pramipexol retard'. Together they form a unique fingerprint.

  • Cite this